Cargando…
Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
Autores principales: | Lelong, Margaux, Nancey, Stephane, Bouguen, Guillaume, Allez, Matthieu, Serrero, Mélanie, Chupin, Antoine, Caillo, Ludovic, Viennot, Stephanie, Blanc, Pierre, Reimund, Jean-Marie, Laharie, David, olivier, Raphael, Peyrin-Biroulet, Laurent, Dib, Nina, Maissin, Astrid de, Montuclard, Celine, Trang-Poisson, Caroline, Gallot, Geraldine, Bressollette-Bodin, Celine, Berthome, Mathilde, Burel, Marianne, Vavasseur, Fabienne, Bourreille, Arnaud, Berre, Catherine Le |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212297/ http://dx.doi.org/10.1016/S0016-5085(22)61412-4 |
Ejemplares similares
-
The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics
por: Lelong, Margaux, et al.
Publicado: (2023) -
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023) -
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022) -
Crohn’s-like acute severe colitis associated with Hermansky-Pudlak syndrome: A case report
por: Girot, Paul, et al.
Publicado: (2019) -
Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)